Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biomea Fusion, Inc.

1.95
+0.230013.37%
Post-market: 1.94-0.0115-0.59%17:00 EDT
Volume:1.06M
Turnover:1.96M
Market Cap:73.27M
PE:-0.51
High:1.95
Open:1.80
Low:1.73
Close:1.72
Loading ...

Insider Buyers Lose Additional US$78k As Biomea Fusion Dips To US$126m

Simply Wall St.
·
13 Feb

Biomea Fusion, Inc. (NASDAQ:BMEA) is a favorite amongst institutional investors who own 51%

Simply Wall St.
·
05 Feb

Biomea Fusion Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Jan

Biomea Fusion’s Strategic Focus on Metabolic Diseases and Promising Pipeline Advances Garner Buy Rating

TIPRANKS
·
14 Jan

Biomea Fusion Is Maintained at Buy by D. Boral Capital

Dow Jones
·
14 Jan

Biomea Fusion price target lowered to $16 from $128 at D. Boral Capital

TIPRANKS
·
13 Jan

Biomea Fusion to become diabetes, obesity medicines company

TIPRANKS
·
13 Jan

Biomea Fusion Inc: Plans to Conclude Its Studies Exploring Icovamenib's Potential in Oncology

THOMSON REUTERS
·
13 Jan

Biomea Fusion to Become a Diabetes & Obesity Medicines Company

THOMSON REUTERS
·
13 Jan

Biomea Fusion: Based on Most Recent Trial Results, Strategic Focus for Icovamenib Will Be in Metabolic Disorders

THOMSON REUTERS
·
13 Jan

3 US Penny Stocks With Market Caps Up To $2B

Simply Wall St.
·
09 Jan

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Biomea Fusion (BMEA) and Solid Biosciences (SLDB)

TIPRANKS
·
09 Jan

Scotiabank Sticks to Its Buy Rating for Biomea Fusion (BMEA)

TIPRANKS
·
08 Jan

Biomea Fusion reports new preclinical data on icovamenib-semaglutide study

TIPRANKS
·
07 Jan

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

THOMSON REUTERS
·
07 Jan

Biomea Fusion Inc - Icovamenib With Semaglutide Shows 11.5% Body Weight Reduction

THOMSON REUTERS
·
07 Jan

Here’s Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10

Insider Monkey
·
06 Jan

Biomea Fusion Advances Diabetes Treatment with Positive Study Results

TIPRANKS
·
21 Dec 2024

Biomea Fusion Is Maintained at Buy by D. Boral Capital

Dow Jones
·
19 Dec 2024

Biomea Fusion Inc : Scotiabank Cuts Target Price to $30 From $41

THOMSON REUTERS
·
18 Dec 2024